Previous Close | 2.7600 |
Open | 2.7600 |
Bid | 1.9500 x N/A |
Ask | 2.0200 x N/A |
Day's Range | 2.7600 - 2.7600 |
52 Week Range | 1.7100 - 2.8800 |
Volume | |
Avg. Volume | 10 |
Market Cap | 71.576M |
Beta (5Y Monthly) | -0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.00 |
AUSTIN, Texas, May 15, 2024--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2024, and recent updates.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
AUSTIN, Texas, February 13, 2024--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates